Study S001398

Efficacy and Safety of Omarigliptin, A Weekly Dipeptidyl Peptidase-4 Inhibitor for Type 2 Diabetes Management: Real-World Evaluation in Bangladesh

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT06449235
Study type: INTERVENTIONAL
Allocation: NON_RANDOMIZED
Phase: PHASE4
Masking: NONE
Status: UNKNOWN
Enrollment: 938
Start: 2024-09
Primary completion: 2025-04
Lead sponsor: Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders
Conditions: Type2diabetes
Interventions: DRUG:Omarigliptin; DRUG:Sulphonylureas; DRUG:Metformin; DRUG:Other DPP4-i; DRUG:Thiazolidinediones; DRUG:Alpha-Glucosidase Inhibitor; DRUG:Glucagon-Like Peptide-1; DRUG:Receptor Agonists (GLP1RA); DRUG:SGLT2 inhibitors
Results posted: FALSE
Individual participant data sharing: UNDECIDED
Secondary identifiers: OTHER:BADAS-ERC/EC/24/13

Registered primary outcomes

Glycemic Control as Measured by HbA1c Levels [Baseline assessment. Follow-up visits at 14 days, 3 months, and 6 months post-enrollment.]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.